Resistant Starch: Types, Human Evidence and Limits

A 2023 review identified 36 randomized trials in people with type 2 diabetes or prediabetes. Some RS1 and RS2 interventions improved glucose measures, but results varied and evidence for other types was more limited. The pooled findings did not establish a clear HbA1c benefit, a longer-term glucose measure; the authors also flagged bias, inconsistent carbohydrate reporting and uncertain clinical importance.^{See reference 1}

A 2025 review included 23 randomized trials in adults with metabolic-syndrome-related risks, with 19 pooled. Some lipid and body-measure outcomes improved, and the HbA1c change was small. Pooled body weight was not significantly reduced. Insulin-resistance findings varied substantially between studies. These selected adult groups and measured endpoints do not establish that an unspecified powder treats diabetes or reliably causes weight loss.^{See reference 3}

A 2024 crossover trial studied 37 adults with overweight or obesity. Eight weeks of high-amylose maize RS2 provided 40 g of resistant starch daily, within a controlled background diet. Compared with the control-starch period, the net average weight change was about −2.8 kg. The study preparation weighed 91.2 g to supply that 40 g of resistant starch, illustrating why powder weight and resistant-starch content differ.^{See reference 2}

The researchers noted the small sample and strict eligibility criteria, and weight returned toward baseline during the washout in one sequence. The result is promising under those conditions, not a forecast or intake recommendation. Human microbiome associations were followed by mechanistic experiments in mice; those experiments do not establish that adding a particular probiotic will reproduce the human effect.^{See reference 2}

A 2022 review of 39 adult trials examined tolerability and short-chain fatty acids, compounds produced during gut fermentation. Responses were not uniform and tolerability reporting was incomplete. A change in a bacterial group or a stool metabolite does not itself establish improved symptoms or long-term disease prevention.^{See reference 4}

A September 2026 review considered both glucomannan and resistant starch across mixed study designs: 11 of its 20 included studies were in animals. It described heterogeneous findings and limited direct evidence for benefit from combining the two ingredients. Such mixed mechanistic evidence should not be presented as a proven human weight-loss formula.^{See reference 5}

Check the named source and type, whether the ingredient is a prepared extract or ordinary flour, and how the label states resistant-starch content. Processing and preparation are part of the evidence. The picture depicts source ingredients and plain powder; it does not measure their resistant-starch content or recommend eating raw potato.

Cooking and cooling is a scientific explanation for RS3, not a storage or food-safety protocol. Do not infer a resistant-starch amount, a carbohydrate subtraction for insulin dosing, or a safe preparation method from this guide.

Many trials in the tolerability review reported acceptable tolerance, but not all studies measured or reported it consistently. The 2023 review also highlights incomplete side-effect reporting. Gastrointestinal response and suitability remain relevant; evidence from selected adults cannot be extended automatically to children, pregnancy or every digestive condition.^{See reference 4,See reference 1}

NCCIH advises discussing supplements with the care team because products can cause problems in particular medical circumstances or with medicines. This guide does not prescribe an amount, replace diabetes treatment or clear a product for an allergy or digestive condition.^{See reference 6}